Related Experiment Video

Updated: Jun 10, 2026

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection
06:56

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

Published on: February 20, 2020

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

Elizabeth B Hirsch1, Vincent H Tam

  • 1University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.

Expert Review of Pharmacoeconomics & Outcomes Research
|August 19, 2010
PubMed

Insights

Antibiotic resistance in Pseudomonas aeruginosa is rising globally. This review examines patient outcomes, mortality, and economic impacts of multidrug-resistant (MDR) P. aeruginosa infections, highlighting challenges in treatment and comparison.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising global rates of antibiotic resistance in Pseudomonas aeruginosa.
  • Multidrug-resistant (MDR) P. aeruginosa infections pose significant clinical challenges.
  • Lack of a universal definition for MDR complicates literature comparison.

Purpose of the Study:

  • To summarize current literature on patient outcomes associated with drug-resistant P. aeruginosa infections.
  • To examine the impact of antimicrobial therapy on mortality and morbidity.
  • To investigate the economic burden of MDR P. aeruginosa.

Main Methods:

  • Systematic review of contemporary literature.
  • Analysis of studies reporting patient outcomes, mortality, and morbidity.
  • Examination of economic data related to MDR P. aeruginosa infections.

Main Results:

  • Inappropriate empirical therapy linked to increased mortality.
  • Delays in appropriate treatment correlate with longer hospital stays and persistent infections.
  • MDR infections associated with poorer clinical outcomes due to limited treatment options.

Conclusions:

  • Drug-resistant P. aeruginosa infections lead to worse patient outcomes and increased healthcare costs.
  • Effective antimicrobial strategies and clear definitions of MDR are crucial.
  • Further research is needed to address the growing threat of MDR P. aeruginosa.

More Related Videos

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...